A Phase 4 interventional study of Etanercept and Methotrexate in Rheumatoid Arthritis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-18.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing etanercept in Arthritis, Rheumatoid — 4 open to participants now, 5 under way, 1 of them phase 3. Etanercept · Arthritis, Rheumatoid.
Among the 69 studies testing etanercept in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 5 that started in 2004, is one of 39 in phase 4, and was the 8th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 69 studies testing etanercept in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 144 across the 69 interventional studies. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
152 studies in Arthritis, Rheumatoid by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 150 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 29th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2004, is one of 17 in phase 4, and was the 12th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 69 studies testing etanercept in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the long-term safety of the combination of etanercept and methotrexate in adults with RA who have completed the previous double-blind, randomized study.
To evaluate the long-term clinical efficacy and x-ray progression of the combination of etanercept and methotrexate in adults with RA who have completed the previous double-blind, randomized study.
No study locations are listed for this record.
The record gives a start of Jun 2004 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etanercept · Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer →